Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen ...

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

Corcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol ...

When Rita Hunter first asked to meet with me, I had no idea she had been diagnosed with Amyotrophic Lateral Sclerosis (ALS) ...

Amyotrophic lateral sclerosis (ALS) is a rare neurological disorder that affects specific nerve cells in the spinal cord known as motor neurons. Symptoms involve issues with swallowing and speech ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe e ...

Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.

Therapeutics announced it has concluded a Type C meeting with the FDA for PrimeC in the treatment of amyotrophic lateral ...

The global amyotrophic lateral sclerosis treatment market size was US$ 637.2 million in 2021. The global amyotrophic lateral sclerosis treatment market is forecast to grow to US$ 918 million by 2030, ...